Biotech

Regeneus Ltd (ASX:RGS) Featured in Morgans' 'Under The Microscope' Podcast series

🕔7/11/2020 9:00:15 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, was recently featured in the 'Under the Microscope' podcast series from Morgans.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Partnering Update

🕔6/23/2020 1:04:50 PM

Anatara is nearing conclusion of a process of due diligence and negotiation with many of the world's leading animal health companies. Anatara's objective being to partner with a company or companies to register Detach(R) in key overseas markets.

Read Full Article

IQX Limited (NSX:IQX) Notice of EGM

🕔6/10/2020 4:16:00 PM

Notice is hereby given that an Extraordinary General Meeting (EGM) of iQX Limited (NSX:IQX) will be held at ParkRoyal Darling Harbour at 10.00am (AEST) on Tuesday 14 July 2020.

Read Full Article

IQX Limited (NSX:IQX) COVID-19 Diagnostic Test With Harvard University

🕔6/9/2020 3:12:00 PM

iQX Limited (iQX Ltd) (NSX:IQX) would like to announce a collaboration agreement between the Wyss Institute for Biologically Inspired Engineering, Harvard University, and Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which iQX Ltd holds a 19% equity position.

Read Full Article

Regeneus Ltd (ASX:RGS) Director Resignation

🕔6/4/2020 10:53:55 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that non-executive director Dr Glen Richards has resigned to allow him to focus on his other commitments.

Read Full Article

Regeneus Ltd (ASX:RGS) Kyocera completes Progenza Due Diligence

🕔5/18/2020 8:39:52 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it has received notification that Kyocera Corporation (TYO:6971) has completed its due diligence process on its lead stem cell platform technology Progenza for treatment of Knee Osteoarthritis (Progenza OA).

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔4/29/2020 10:35:36 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its quarterly cashflow report and review of operational activities for the period ending 31 March 2020.

Read Full Article